{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T22:06:33Z","timestamp":1776722793777,"version":"3.51.2"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,26]]},"DOI":"10.7759\/cureus.105940","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T05:34:51Z","timestamp":1774589691000},"source":"Crossref","is-referenced-by-count":1,"title":["Metastatic Colorectal Cancer as a Chronic Disease: Twelve-Year Survival After Initially Unresectable Bilobar Liver Metastases"],"prefix":"10.7759","author":[{"given":"Thomas","family":"Mathew","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathew","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.9273","article-title":"Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?","volume":"27","author":"Adam R","year":"2009","unstructured":"Adam R, Wicherts DA, de Haas RJ, et al.. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?. J Clin Oncol. 2009, 27:1829-35. 10.1200\/JCO.2008.19.9273","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem E","year":"2016","unstructured":"Van Cutsem E, Cervantes A, Adam R, et al.. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016, 27:1386-422. 10.1093\/annonc\/mdw235","journal-title":"Ann Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu088","article-title":"Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX\/cetuximab or FOLFIRI\/cetuximab in a multidisciplinary concept (CELIM study)","volume":"25","author":"Folprecht G","year":"2014","unstructured":"Folprecht G, Gruenberger T, Bechstein W, et al.. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX\/cetuximab or FOLFIRI\/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol. 2014, 25:1018-25. 10.1093\/annonc\/mdu088","journal-title":"Ann Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/bjs5.50299","article-title":"Incidence and management of patients with colorectal cancer and synchronous and metachronous colorectal metastases: a population-based study","volume":"4","author":"V\u00e4yrynen V","year":"2020","unstructured":"V\u00e4yrynen V, Wirta EV, Sepp\u00e4l\u00e4 T, Sihvo E, Mecklin JP, Vasala K, Kellokumpu I. Incidence and management of patients with colorectal cancer and synchronous and metachronous colorectal metastases: a population-based study. BJS Open. 2020, 4:685-92. 10.1002\/bjs5.50299","journal-title":"BJS Open"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.218","article-title":"Long-term outcomes of patients with 10 or more colorectal liver metastases","volume":"117","author":"Allard MA","year":"2017","unstructured":"Allard MA, Adam R, Giuliante F, et al.. Long-term outcomes of patients with 10 or more colorectal liver metastases. Br J Cancer. 2017, 117:604-11. 10.1038\/bjc.2017.218","journal-title":"Br J Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0012","article-title":"Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Benson AB","year":"2021","unstructured":"Benson AB, Venook AP, Al-Hawary MM, et al.. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021, 19:329-59. 10.6004\/jnccn.2021.0012","journal-title":"J Natl Compr Canc Netw"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2020.09.008","article-title":"Regional therapies for colorectal liver metastases: systematic review and clinical practice guideline","volume":"20","author":"Karanicolas P","year":"2021","unstructured":"Karanicolas P, Beecroft JR, Cosby R, et al.. Regional therapies for colorectal liver metastases: systematic review and clinical practice guideline. Clin Colorectal Cancer. 2021, 20:20-8. 10.1016\/j.clcc.2020.09.008","journal-title":"Clin Colorectal Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0006-0","article-title":"A phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours","volume":"118","author":"Dredge K","year":"2018","unstructured":"Dredge K, Brennan TV, Hammond E, et al.. A phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours. Br J Cancer. 2018, 118:1035-41. 10.1038\/s41416-018-0006-0","journal-title":"Br J Cancer"},{"key":"ref10","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.3504","article-title":"Impact of primary (1\u00b0) tumor location on overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC): analysis of CALGB\/SWOG 80405 (alliance)","volume":"34","author":"Venook AP","year":"2016","unstructured":"Venook AP, Niedzwiecki D, Innocenti F, et al.. Impact of primary (1\u00b0) tumor location on overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC): analysis of CALGB\/SWOG 80405 (alliance). J Clin Oncol. 2016, 34:3504.","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx175","article-title":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials","volume":"28","author":"Arnold D","year":"2017","unstructured":"Arnold D, Lueza B, Douillard JY, et al.. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017, 28:1713-29. 10.1093\/annonc\/mdx175","journal-title":"Ann Oncol"},{"key":"ref12","article-title":"Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed\/\u200bRefractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) [Thesis]","author":"Davar D","year":"2025","unstructured":"Davar D. Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed\/\u200bRefractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) [Thesis]. University of Pittsburgh, Pittsburgh; 2025."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5603\/OCP.2018.0001","article-title":"Management of nivolumab-induced pulmonary toxicity-pneumonitis","volume":"14","author":"Knetki-Wr\u00f3blewska M","year":"2018","unstructured":"Knetki-Wr\u00f3blewska M, Kowalski DM. Management of nivolumab-induced pulmonary toxicity-pneumonitis. Oncol Clin Pract. 2018, 14:35-9. 10.5603\/OCP.2018.0001","journal-title":"Oncol Clin Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/456537-metastatic-colorectal-cancer-as-a-chronic-disease-twelve-year-survival-after-initially-unresectable-bilobar-liver-metastases","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T05:34:52Z","timestamp":1774589692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/456537-metastatic-colorectal-cancer-as-a-chronic-disease-twelve-year-survival-after-initially-unresectable-bilobar-liver-metastases"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.105940","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,26]]}}}